Propofol EC50 for Inducing Loss of Consciousness in General Combined Epidural Anesthesia
Gastric Cancer
Bottom Line
View on ClinicalTrials.gov: NCT05124704 ↗Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- 5-8ml 0.375% ropivacaine (Drug); 5-8ml normal saline (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Wang Jiangling
- Primary completion
- May 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Propofol EC50 for Inducing Loss of Conciousness |
2.97; 3.36 | — |
| PRIMARY Predicted Effect-site Concentration of Propofol (Ceprop) at Certain Time Points |
2.63; 1.97 | — |
| SECONDARY Anesthetics Consumption |
0.11; 0.13 | — |
| SECONDARY Postoperative Exhaust Time |
78.0; 85.0 | — |
Summary
Eligibility Criteria
Inclusion Criteria
Gastric cancer patients age between 18-75 yrs;
ASA physical state I and II
Undergoing open gastrectomy
Exclusion Criteria
With contraindications to epidural puncture or catheter placement
Chronic or acute (within 48 h) intake of psychotropic drugs, benzodiazepines, anticonvulsants, or opioids; alcoholism
Hepatic, renal, neurological or other organ dysfunctiony
Younger than 18 years or older than 75 years
Allergic to local anesthetic solutions or opioids
Received neo-adjuvant chemotherapy
Refuse to receive epidural puncture
Data sourced from ClinicalTrials.gov (NCT05124704). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.